Jefferies maintains Cigna Group at Hold, raises price target to $304 from $288

Jefferies kept Cigna Group at Hold but raised its price target to $304 from $288. The new target is close to Cigna's recent closing price of $301.45. Other recent analyst targets for Cigna range from $320 to $390.

Original reporting
Published Nov 12, 2026, 6:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 6:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jefferies maintains Cigna Group at Hold, raises price target to $304 from $288 — source image
Decision brief

The 30-second read

$CIBullishMed
01

Why it matters

The upgrade may prompt short‑term buying, but without fresh fundamentals the effect could be limited.

02

Market read

Analyst target change provides a modest trading signal for CI, with limited broader market impact.

03

What to watch

No new earnings or guidance data accompany the upgrade; the move relies solely on analyst opinion.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Jefferies maintains a Hold rating on Cigna but adjusts its price target upward, reflecting a modestly improved outlook.

Company-level read

Ticker impact

$CIBullishMedium confidence
Context

Jefferies raised its price target for Cigna Group to $304 from $288, indicating a more favorable outlook.

Expected impact

likely modest upside pressure as investors price in the higher target

Evidence & confidence

Analyst target upgrades typically lead to short‑term buying interest, especially when the new target is above recent close.

Market effects

May lift sentiment in the health‑insurance sector.

U.S. market focus, limited regional effect.

Low global relevance.

Counterpoint

Target raise could be premature if underlying earnings guidance remains weak.

Key entities

  • Cigna Group

    U.S. health services and insurance company (ticker CI).

  • Jefferies

    Equity research firm providing the rating and target update.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.